By David Douglas NEW YORK (Reuters Health) – Adding lapatinib to paclitaxel provided significant benefits to women with newly diagnosed HER2-positive metastatic breast cancer in a recent study.…
NEW YORK (Reuters Health) – For women with HER2-positive breast cancer, trastuzumab is as beneficial in those with invasive lobular disease as those with invasive ductal carcinoma, according…
NEW YORK (Reuters Health) – A European study indicates that patients with T-cell prolymphocytic leukemia may respond well to induction chemotherapy using fludarabine, mitoxantrone and cyclophosphamide, followed by…
By Andrew M. Seaman New York (Reuters Health) – Women with lung cancer who ate the most soy before their diagnosis might live a little longer than those…
NEW YORK (Reuters Health) – Environmental factors appear to influence the incidence of papillary thyroid microcarcinomas (PTMCs), according to a comparison of epidemiologic data from Sicily and the…
NEW YORK (Reuters Health) – In a randomized controlled trial, the anti-CA-125 vaccine abagovomab did not prolong survival in patients with ovarian cancer in first remission — despite…
NEW YORK (Reuters Health) – Even without conventional conditioning and cytoxic chemotherapy, an allogeneic hematopoietic cell transplant (HCT) can have a substantial benefit in patients with advanced hematologic…
NEW YORK (Reuters Health) – Intraperitoneal chemotherapy may significantly improve long-term survival in ovarian cancer patients, a new study found. Data from 876 patients followed for a median…
NEW YORK (Reuters Health) – The risk of arterial thromboembollic events related to bevacizumab treatment of colorectal cancer (CRC) in older patients is moderate in general practice, and…
NEW YORK (Reuters Health) – In cancer patients with a central venous catheter (CVC), the occurrence of a related infection or thrombosis can often be resolved while the…